Cantharidin Application in Molluscum Patients-1 (CAMP-1)

• ClinicalTrials.gov Identifier: NCT03377790
• Recruitment Status: Completed
• First Posted: December 19, 2017
• Results First Posted: December 14, 2021
• Last Update Posted: January 11, 2022
• Sponsor: Verrica Pharmaceuticals Inc.
• Collaborators: Instat Consulting, Inc.; Paidion Research, Inc.; Database Integrations, Inc.
• Information provided by (Responsible Party): Verrica Pharmaceuticals Inc.

• Study Type: Interventional
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Molluscum Contagiosum
• Interventions: Combination Product: VP-102 - Cantharidin, Topical Film Forming Solution; Combination Product: Placebo -Topical Film Forming Solution without VP-102
• Enrollment: 266

Participant Flow

Recruitment Details

Pre-study screening for eligibility (ICF and assent, [when applicable], demographics, physical exam, prior and concomitant meds and molluscum and medical hx) could occur up to 14 days before, or on the same day as Study drug application. Subjects not meeting criteria at Treatment Visit 1 were to be discontinued and treated per standard of care. Note: 2 subjects randomized to placebo received VP-102 were included in VP-102 for Safety. There was one subject randomized to VP-102 but not treated.

Pre-assignment Details

Arm/Group Title	VP-102	Placebo
Arm/Group Description	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Period Title: Overall Study
Started	160	106
Completed	150	100
Not Completed	10	6
Reason Not Completed
Withdrawal by Subject	1	0
Adverse Event	1	0
Lost to Follow-up	0	2
Randomized but not treated	1	0
Withdrawn by Parent/Guardian	7	4

Baseline Characteristics

Arm/Group Title		VP-102	Placebo	Total
Arm/Group Description		VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions	Total of all reporting groups
Overall Number of Baseline Participants		160	106	266
Baseline Analysis Population Description		ITT Population
Age, Continuous; Mean (Standard Deviation); Unit of measure: Years
	Number Analyzed	160 participants	106 participants	266 participants
		7.5 (5.29)	6.3 (4.67)	7.4 (5.07)
Sex: Female, Male; Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	160 participants	106 participants	266 participants
	Female	85 53.1%	61 57.5%	146 54.9%
	Male	75 46.9%	45 42.5%	120 45.1%
Ethnicity (NIH/OMB); Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	160 participants	106 participants	266 participants
	Hispanic or Latino	20 12.5%	8 7.5%	28 10.5%
	Not Hispanic or Latino	140 87.5%	98 92.5%	238 89.5%
	Unknown or Not Reported	0 0.0%	0 0.0%	0 0.0%
Race (NIH/OMB); Measure Type: Count of Participants; Unit of measure: Participants
	Number Analyzed	160 participants	106 participants	266 participants
	American Indian or Alaska Native	0 0.0%	0 0.0%	0 0.0%
	Asian	4 2.5%	1 0.9%	5 1.9%
	Native Hawaiian or Other Pacific Islander	0 0.0%	0 0.0%	0 0.0%
	Black or African American	10 6.3%	5 4.7%	15 5.6%
	White	135 84.4%	98 92.5%	233 87.6%
	More than one race	0 0.0%	0 0.0%	0 0.0%
	Unknown or Not Reported	11 6.9%	2 1.9%	13 4.9%
Region of Enrollment; Measure Type: Number; Unit of measure: Participants
United States	Number Analyzed	160 participants	106 participants	266 participants
		160	106	266
Baseline number of treatable molluscum lesions; Mean (Standard Deviation); Unit of measure: Molluscum lesions
	Number Analyzed	160 participants	106 participants	266 participants
		22.2 (23.12)	24.8 (24.97)	23.2 (23.86)

Outcome Measures

1. Primary Outcome

Title	Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)
Description	Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS).
Time Frame	Day 1 (Baseline and new) compared to Day 84 (EOS)

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	74 46.3%	19 17.9%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	Differences between treatments arms are compared using a chi-square test.
	Method	Chi-squared
	Comments	[Not Specified]

2. Secondary Outcome

Title	Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit
Description	Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit.
Time Frame	Day 1 (Baseline and new) compared to Day 63

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	51 31.9%	18 17.0%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0067
	Comments	[Not Specified]
	Method	Chi-squared
	Comments	Differences between treatments arms are compared using a chi-square test.

3. Secondary Outcome

Title	Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit
Description	Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit.
Time Frame	Day 1 (Baseline and new) compared to Day 42

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	33 20.6%	10 9.4%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0152
	Comments	[Not Specified]
	Method	Chi-squared
	Comments	Differences between treatments arms are compared using a chi-square test.

4. Secondary Outcome

Title	Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit
Description	Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit.
Time Frame	Day 1 (Baseline and new) compared to Day 21

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	18 11.3%	4 3.8%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0302
	Comments	[Not Specified]
	Method	Chi-squared
	Comments	Differences between treatments arms are compared using a chi-square test.

5. Other Pre-specified Outcome

Title	Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.
Description	Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the CDLQI, a score of 0-3 was assigned using the following scores per response: 3: Very much (or Prevented School, Question 7 only); 2: Quite a lot; 1: Only a little; 0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome).
Time Frame	Baseline to Day 84 (EOS)

Outcome Measure Data

Analysis Population Description

ITT Population (Subjects 4-16 years of age)

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	122	78
Mean (Standard Deviation); Unit of Measure: units on a scale
	-2.1 (2.70)	-2.7 (3.46)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.5921
	Comments	[Not Specified]
	Method	ANCOVA
	Comments	Differences between Tx arms are compared using an ANCOVA with treatment as the independent factor and baseline CDLQI composite score as the covariate.

6. Other Pre-specified Outcome

Title	Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit
Description	Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit.
Time Frame	Day 1 (Baseline) compared to Day 84 (EOS)

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	157	104
Mean (Standard Deviation); Unit of Measure: percentage of change in wart count
	-69.2 (98.13)	20.0 (239.72)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	ANCOVA
	Comments	Differences between treatment arms are compared using an ANCOVA, with treatment as the independent factor and baseline lesion count as the covariate.

7. Other Pre-specified Outcome

Title	Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
Description	Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit.
Time Frame	Day 1 (Baseline) compared to Day 84 (EOS)

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	157	104
Mean (Standard Deviation); Unit of Measure: change in wart count
	-18.3 (22.64)	-5.9 (33.33)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	ANCOVA
	Comments	Differences between treatment arms are compared using an ANCOVA, with treatment as the independent factor and baseline lesion count as the covariate.

8. Other Pre-specified Outcome

Title	Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
Description	Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit.
Time Frame	Day 1 (Baseline) compared to Day 84 (EOS)

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	119 74.4%	36 34.0%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	Chi-squared
	Comments	Differences between treatments arms are compared using a chi-square test.

9. Other Pre-specified Outcome

Title	Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
Description	Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit.
Time Frame	Day 1 (Baseline) compared to Day 84 (EOS)

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	99 61.9%	28 26.4%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	[Not Specified]
	Method	Chi-squared
	Comments	Differences between treatments arms are compared using a chi-square test.

10. Other Pre-specified Outcome

Title	Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject.
Description	Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions.
Time Frame	Days 1, 21, 42, 63 and 84 (EOS).

Outcome Measure Data

Analysis Population Description

ITT Population

Arm/Group Title	VP-102	Placebo
Arm/Group Description:	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions	Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
Overall Number of Participants Analyzed	160	106
Measure Type: Count of Participants; Unit of Measure: Participants
	9 5.6%	13 12.3%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	VP-102, Placebo
	Comments	[Not Specified]
	Type of Statistical Test	Superiority
	Comments	[Not Specified]
Statistical Test of Hypothesis	P-Value	0.0520
	Comments	[Not Specified]
	Method	Chi-squared
	Comments	Differences between treatments arms are compared using a chi-square test.

Adverse Events

Time Frame	Treatment Visit 1 up to 30 days after EOS Day Visit.
Adverse Event Reporting Description	Note: Related TEAE= TEAEs with relationship of Definitely, Probably or Possibly Related or have a missing relationship. Note: A Local Skin Reaction TEAE is defined as any Targeted AE that was identified as a Related AE. Note: 2 subjects randomized to placebo received VP-102 were included in VP-102 for Safety. There was one subject randomized to VP-102 but not treated.)
Arm/Group Title	VP-102		Placebo
Arm/Group Description	VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions		Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
All-Cause Mortality
	VP-102		Placebo
	Affected / at Risk (%)		Affected / at Risk (%)
Total	0/161 (0.00%)		0/104 (0.00%)
Serious Adverse Events
	VP-102		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/161 (0.00%)		1/104 (0.96%)
Surgical and medical procedures
Serious Treatment Emergent Adverse Events † 1 [1]	0/161 (0.00%)	0	1/104 (0.96%)	1
1 Term from vocabulary, MedDRA; † Indicates events were collected by systematic assessment; [1] Appendicectomy
Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events	5%
	VP-102		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	159/161 (98.76%)		76/104 (73.08%)
Infections and infestations
Pharyngitis streptococcal † 1	6/161 (3.73%)		6/104 (5.77%)
Injury, poisoning and procedural complications
Application site pain † 1	110/161 (68.32%)		20/104 (19.23%)
Application site oedema † 1	21/161 (13.04%)		6/104 (5.77%)
Skin and subcutaneous tissue disorders
Application site pruritus † 1	104/161 (64.60%)		38/104 (36.54%)
Application site erythema † 1	69/161 (42.86%)		30/104 (28.85%)
Application site scab † 1	62/161 (38.51%)		25/104 (24.04%)
Application site discolouration † 1	54/161 (33.54%)		18/104 (17.31%)
Application site dryness † 1	24/161 (14.91%)		11/104 (10.58%)
Application site erosion † 1	10/161 (6.21%)		2/104 (1.92%)
Application site scar † 1	7/161 (4.35%)		5/104 (4.81%)
Pruritus † 1	4/161 (2.48%)		5/104 (4.81%)
Application site vesicles † 1	157/161 (97.52%)		29/104 (27.88%)
1 Term from vocabulary, MedDRA 20.0; † Indicates events were collected by systematic assessment

Limitations and Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

PI is bound to terms and conditions of a Sponsored Clinical Trial Agreement which has strict confidentiality obligations running to Sponsor and broad provisions restricting PI's rights to publish or present any data or Study Results without Sponsor's express review consent and review.

Results Point of Contact

• Name/Title: Susan Cutler, VP, Medical Affairs
• Organization: Verrica Pharmaceuticals
• Phone: 484-773-0898
• EMail: scutler@verrica.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Eichenfield LF, Kwong P, Gonzalez ME, Yan A, D'Arnaud P, Burnett P, Olivadoti M. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials. J Clin Aesthet Dermatol. 2021 Oct;14(10):42-47.

Eichenfield LF, Siegfried E, Kwong P, McBride M, Rieger J, Glover D, Willson C, Davidson M, Burnett P, Olivadoti M. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021 Mar;22(2):257-265. doi: 10.1007/s40257-020-00570-8. Epub 2021 Feb 18.

Eichenfield LF, McFalda W, Brabec B, Siegfried E, Kwong P, McBride M, Rieger J, Willson C, Davidson M, Burnett P. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020 Dec 1;156(12):1315-1323. doi: 10.1001/jamadermatol.2020.3238.

• Responsible Party: Verrica Pharmaceuticals Inc.
• ClinicalTrials.gov Identifier: NCT03377790
• Other Study ID Numbers: VP-102-101
• First Submitted: December 13, 2017
• First Posted: December 19, 2017
• Results First Submitted: October 12, 2021
• Results First Posted: December 14, 2021
• Last Update Posted: January 11, 2022